Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ethyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof

1 - 24 . (canceled) 
     
     
         25 . A process for the preparation of a crystalline polymorph of 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide dihydrochloride, the process comprising crystallizing 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide dihydrochloride from a mixture of acetonitrile and water. 
     
     
         26 . The process of  claim 25 , wherein the process further comprises isolating the crystalline polymorph by filtration, without drying. 
     
     
         27 . The process of  claim 25 , wherein the crystalline polymorph is characterized by X-ray powder diffraction peaks at least at 6.46, 20.26, and 26.68°2θ±0.1°2θ. 
     
     
         28 . The process of  claim 27 , wherein the crystalline polymorph is further characterized by an X-ray powder diffraction peaks at 22.27°2θ±0.1°2θ. 
     
     
         29 . The process of  claim 28 , wherein the crystalline polymorph is further characterized by at least two X-ray powder diffraction peaks at 9.78, 16.57, or 19.58°2θ±0.1°2θ. 
     
     
         30 . The process of  claim 25 , wherein the crystalline polymorph presents itself as columnar particles. 
     
     
         31 . The process of  claim 25 , wherein the crystalline polymorph comprises less than 5% by weight of the monohydrate polymorph. 
     
     
         32 . The process of  claim 25 , wherein the crystalline polymorph comprises less than 3% by weight of the monohydrate polymorph. 
     
     
         33 . The process of  claim 25 , wherein the crystalline polymorph comprises less than 1% by weight of the monohydrate polymorph. 
     
     
         34 . The process of  claim 25 , wherein the crystalline polymorph comprises less than 0.5% by weight of the monohydrate polymorph. 
     
     
         35 . The process of  claim 25 , wherein the crystalline polymorph comprises less than 5% by weight of amorphous 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide dihydrochloride. 
     
     
         36 . The process of  claim 25 , wherein the crystalline polymorph comprises less than 3% by weight of amorphous 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide dihydrochloride. 
     
     
         37 . The process of  claim 25 , wherein the crystalline polymorph comprises less than 1% by weight of amorphous 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide dihydrochloride. 
     
     
         38 . The process of  claim 25 , wherein the crystalline polymorph comprises less than 0.5% by weight of amorphous 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide dihydrochloride. 
     
     
         39 . The process of  claim 25 , wherein the process comprises:
 suspending 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide dihydrochloride in acetonitrile;   heating the suspension to reflux;   adding water until the mixture is homogenous; and   precipitating the crystalline polymorph from the solution by cooling and/or reducing the volume of the solution.   
     
     
         40 . A process for the preparation of a crystalline polymorph of 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide dihydrochloride, the process comprising crystallizing 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide dihydrochloride from a mixture of ethanol and water. 
     
     
         41 . The process of  claim 40 , wherein the crystalline polymorph is characterized by X-ray powder diffraction peaks at least at 6.46, 20.26, and 26.68°2θ±0.1°2θ. 
     
     
         42 . The process of  claim 41 , wherein the crystalline polymorph is further characterized by an X-ray powder diffraction peaks at 22.27°2θ±0.1°2θ. 
     
     
         43 . The process of  claim 42 , wherein the crystalline polymorph is further characterized by at least two X-ray powder diffraction peaks at 9.78, 16.57, or 19.58°2θ±0.1°2θ.